MAGNITUDE-2 – Talk Bio

Actionable Insights Powered by AI

FDA Lifts Clinical Hold on Intellia’s MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN

FDA; Intellia Therapeutics; clinical hold; MAGNITUDE-2; nex-z; ATTRv-PN; gene editing; CRISPR